

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/722,776	11/27/2000	Joong Yeong Jeon	9250-2	4908	
75	590 01/28/2002				
ROBERT J. SACCO Akerman, Senterfitt & Eidson, P.A. 222 Lakeview Avenue - 4th Floor			EXAMINER		
			FIELDS, IESHA P		
P.O. Box 3188 West Palm Beach, FL 33402-3188			ART UNIT	PAPER NUMBER	
	,		1645		
			DATE MAIL ED: 01/28/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/722,776	JEON ET AL.
Offic Action Summary	Examiner	Art Unit
	lesha P Fields	1645
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with	the correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a rep y within the statutory minimum of thirty will apply and will expire SIX (6) MONT in, cause the application to become ABA	oly be timely filed (30) days will be considered timely. IS from the mailing date of this communication. NDONED (35 U.S.C. § 133).
Responsive to communication(s) filed on		
· · · · · · · · · · · · · · · · · · ·	is action is non-final.	
Since this application is in condition for allowated in accordance with the practice under	ance except for formal matte	
Disposition of Claims		
4) Claim(s) is/are pending in the application	on.	
4a) Of the above claim(s) is/are withdraw	wn from consideration.	
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) 1-12 are subject to restriction and/or	election requirement.	
Application Papers		
9) The specification is objected to by the Examine	r.	
10)☐ The drawing(s) filed on is/are: a)☐ accept	oted or b) objected to by the	e Examiner.
Applicant may not request that any objection to the		* 1
11)☐ The proposed drawing correction filed on	_ is: a)☐ approved b)☐ dis	approved by the Examiner.
If approved, corrected drawings are required in rep	•	
12) The oath or declaration is objected to by the Ex	aminer.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C. §	119(a)-(d) or (f).
a)☐ All b)☐ Some * c)☐ None of:		
1. Certified copies of the priority documents	s have been received.	
2. Certified copies of the priority documents	s have been received in Ap	plication No
 3. Copies of the certified copies of the prior application from the International Bu * See the attached detailed Office action for a list 	reau (PCT Rule 17.2(a)).	_
14) Acknowledgment is made of a claim for domesti	· ·	ž ·
a) The translation of the foreign language pro		
Attachment(s)		· -
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of In	ummary (PTO-413) Paper No(s) formal Patent Application (PTO-152)

Application/Control Number: 09/722,776

Art Unit: 1645

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-6 and 9-12, drawn to an enzyme, classified in class 435, subclass 183.
- Claim 7, drawn to a process of producing an enzyme, classified in class435, subclass 4.
- III. Claims 8, drawn to an immunogenic composition, classified in class 435, subclass 69.3.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the enzyme could be used to produce antibodies.

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different

Application/Control Number: 09/722,776

Art Unit: 1645

process of using that product (MPEP § 806.05(h)). In the instant case the enzyme could be used in a kit.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their separate classification and their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to lesha Fields whose telephone number is (703) 306-3225.

lesha Fields

January 25, 2002

MARK NAVARRO PRIMARY EXAMINER Page 3



Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE FIRST NAMED APPLICANT			ATTORNEY DOCKET NO.	
	<u> </u>	1	EXAMINE	AMINER	
•			ART UNIT	PAPER NUMBER	

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN ONE EXTENDIBLE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Applicant is requested to return a copy of the attached to the examiner should be Any inquiry concerning this communication or earlier communications from the examiner should be directed to whose telephone number is (703) 30